Ascletis to Showcase ASC47, ASC36 and ASC35 Obesity Therapies at ECO 2026; Combo Trial Shows 111.8% Higher Relative Weight Loss vs. Semaglutide Alone

Bulletin Express08:02

Ascletis Pharma Inc. (Ascletis) has issued a voluntary announcement confirming three poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled for 12–15 May 2026 in Istanbul. All data are drawn directly from the company’s disclosure.

Ascletis will present Phase I results for ASC47, an adipose-targeting thyroid hormone receptor-β agonist designed for muscle-preserving weight loss. In combination with semaglutide, ASC47 delivered up to 111.80% greater relative weight loss in participants with obesity compared with semaglutide monotherapy.

Pre-clinical data will also be released on ASC36, a once-monthly next-generation amylin receptor agonist peptide. In non-human primate studies, ASC36 achieved a 32-day average observed half-life—six times longer than petrelintide—and produced 91% greater relative weight loss than petrelintide in diet-induced obese (DIO) rat models.

A third poster will cover ASC35, a once-monthly GLP-1R/GIPR dual agonist peptide. In non-human primates, ASC35 recorded a 14-day average observed half-life—six times longer than tirzepatide—and achieved 71% greater relative weight loss than tirzepatide in DIO mouse models.

All three presentations fall under Track 4: Obesity Management and Intervention and will be held on Thursday, 14 May 2026, from 18:00 to 19:15 TRT. Ascletis cautions that successful development, manufacturing and commercialisation of ASC47, ASC36 and ASC35 are not guaranteed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113627205?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 08:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113627205","market":"hk","top_or_hot":-1,"title":"Ascletis to Showcase ASC47, ASC36 and ASC35 Obesity Therapies at ECO 2026; Combo Trial Shows 111.8% Higher Relative Weight Loss vs. Semaglutide Alone","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. (Ascletis) has issued a voluntary announcement confirming three poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled for 12–15 May 2026 in Istanbul. All data are drawn directly from the company’s disclosure.</p>\n<p>Ascletis will present Phase I results for ASC47, an adipose-targeting thyroid hormone receptor-β agonist designed for muscle-preserving weight loss. In combination with semaglutide, ASC47 delivered up to 111.80% greater relative weight loss in participants with obesity compared with semaglutide monotherapy.</p>\n<p>Pre-clinical data will also be released on ASC36, a once-monthly next-generation amylin receptor agonist peptide. In non-human primate studies, ASC36 achieved a 32-day average observed half-life—six times longer than petrelintide—and produced 91% greater relative weight loss than petrelintide in diet-induced obese (DIO) rat models.</p>\n<p>A third poster will cover ASC35, a once-monthly GLP-1R/GIPR dual agonist peptide. In non-human primates, ASC35 recorded a 14-day average observed half-life—six times longer than tirzepatide—and achieved 71% greater relative weight loss than tirzepatide in DIO mouse models.</p>\n<p>All three presentations fall under Track 4: Obesity Management and Intervention and will be held on Thursday, 14 May 2026, from 18:00 to 19:15 TRT. Ascletis cautions that successful development, manufacturing and commercialisation of ASC47, ASC36 and ASC35 are not guaranteed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis to Showcase ASC47, ASC36 and ASC35 Obesity Therapies at ECO 2026; Combo Trial Shows 111.8% Higher Relative Weight Loss vs. Semaglutide Alone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis to Showcase ASC47, ASC36 and ASC35 Obesity Therapies at ECO 2026; Combo Trial Shows 111.8% Higher Relative Weight Loss vs. Semaglutide Alone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 08:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma Inc. (Ascletis) has issued a voluntary announcement confirming three poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled for 12–15 May 2026 in Istanbul. All data are drawn directly from the company’s disclosure.</p>\n<p>Ascletis will present Phase I results for ASC47, an adipose-targeting thyroid hormone receptor-β agonist designed for muscle-preserving weight loss. In combination with semaglutide, ASC47 delivered up to 111.80% greater relative weight loss in participants with obesity compared with semaglutide monotherapy.</p>\n<p>Pre-clinical data will also be released on ASC36, a once-monthly next-generation amylin receptor agonist peptide. In non-human primate studies, ASC36 achieved a 32-day average observed half-life—six times longer than petrelintide—and produced 91% greater relative weight loss than petrelintide in diet-induced obese (DIO) rat models.</p>\n<p>A third poster will cover ASC35, a once-monthly GLP-1R/GIPR dual agonist peptide. In non-human primates, ASC35 recorded a 14-day average observed half-life—six times longer than tirzepatide—and achieved 71% greater relative weight loss than tirzepatide in DIO mouse models.</p>\n<p>All three presentations fall under Track 4: Obesity Management and Intervention and will be held on Thursday, 14 May 2026, from 18:00 to 19:15 TRT. Ascletis cautions that successful development, manufacturing and commercialisation of ASC47, ASC36 and ASC35 are not guaranteed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1113627205","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113627205","pubTimestamp":1778025777,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. (Ascletis) has issued a voluntary announcement confirming three poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled for 12–15 May 2026 in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼将在ECO 2026上展示ASC47、ASC36和ASC35肥胖疗法；Combo试验显示相对体重减轻比单独使用索马鲁肽高111.8%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. (Ascletis) has issued a voluntary announcement confirming three poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled for 12–15 May 2026 in Istanbul. All data are drawn directly from the company’s disclosure.\nAscletis will present Phase I results for ASC47, an adipose-targeting thyroid hormone receptor-β agonist designed for muscle-preserving weight loss. In combination with semaglutide, ASC47 delivered up to 111.80% greater relative weight loss in participants with obesity compared with semaglutide monotherapy.\nPre-clinical data will also be released on ASC36, a once-monthly next-generation amylin receptor agonist peptide. In non-human primate studies, ASC36 achieved a 32-day average observed half-life—six times longer than petrelintide—and produced 91% greater relative weight loss than petrelintide in diet-induced obese (DIO) rat models.\nA third poster will cover ASC35, a once-monthly GLP-1R/GIPR dual agonist peptide. In non-human primates, ASC35 recorded a 14-day average observed half-life—six times longer than tirzepatide—and achieved 71% greater relative weight loss than tirzepatide in DIO mouse models.\nAll three presentations fall under Track 4: Obesity Management and Intervention and will be held on Thursday, 14 May 2026, from 18:00 to 19:15 TRT. Ascletis cautions that successful development, manufacturing and commercialisation of ASC47, ASC36 and ASC35 are not guaranteed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113627205","isCrawlerRequest":true}